Intervention

Latanoprost

ClinicalTrials.gov intervention label

Clinical trials31

Recruiting0

Common conditions18

Lead sponsors shown15

Clinical trials

31 shown

A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in ChinaNCT06666855 · 2024-11-28

ACTIVE_NOT_RECRUITING

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351NCT03762369 · 2018-12-07

CATS Tonometer IOP Reduction Latanoprost Verses TimololNCT04178863 · 2018-07-01

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)NCT04737928 · 2018-04-02

A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension PatientsNCT03419975 · 2016-04-26

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).NCT02622334 · 2015-12-29

Stop Retinal Ganglion Cell Dysfunction StudyNCT02390284 · 2015-09-01

28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular HypertensionNCT02531152 · 2015-09-01

A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)NCT02083289 · 2014-05-01

Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle GlaucomaNCT03966560 · 2014-01-01

Blood Flow of Ophthalmic Artery and GlaucomaNCT02656979 · 2013-12-01

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle GlaucomaNCT01917383 · 2013-08-01

Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by LatanoprostNCT01896180 · 2013-07-01

Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OHNCT01721707 · 2012-12-01

Switching From Preserved to Preserved-free Treatments for Glaucoma.NCT01433900 · 2012-05-01

Clinical Evaluation of Efficacy of SLT to Topical Medication in Lowering IOPNCT01639807 · 2011-10-01

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular HypertensionNCT01410188 · 2011-09-01

Effects of Anti-Glaucoma Medications on the Ocular SurfaceNCT01315574 · 2011-02-01

Safety Study of Latanoprost Slow Release InsertNCT01180062 · 2011-01-01

Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular HypertensionNCT01223378 · 2010-12-13

Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface DiseaseNCT01254370 · 2010-11-01

Topical Application of Latanoprost in Diabetic RetinopathyNCT01225653 · 2010-11-01

Efficacy Comparison of Xalatan and Azopt on POAG and OHNCT01084902 · 2010-02-01

Central Corneal Thickness and 24-hour Fluctuation of Intraocular PressureNCT00941525 · 2009-09-01

A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)NCT00821002 · 2009-01-01

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular HypertensionNCT00846989 · 2009-01-01

Circadian Rhythms of Aqueous Humor Dynamics in HumansNCT00572936 · 2006-03-13

Comparison of Latanoprost Vs. TimololNCT00579969 · 2003-12-01

A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle GlaucomaNCT00647101 · 2003-12-01

24-hour Control of Intraocular Pressure (IOP) in Ocular HypertensionNCT01655758 · 2002-01-01

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)NCT00051142 · 2001-02-01

Common conditions

Ocular Hypertension15 Glaucoma10 Glaucoma, Open-Angle3 Open Angle Glaucoma3 Primary Open-angle Glaucoma3 Ocular Hypertension (OHT)2 Diabetic Retinopathy1 Elevated Intraocular Pressure1 Glaucoma, Primary Open Angle1 Glaucoma; Drugs1 Intraocular Pressure1 Ocular Surface Disease1 Open Angle Glaucoma -Ocular Hypertension1 Open Angle-glaucoma1 Open-Angle Glaucoma1 Primary Open Angle Glaucoma1 Primary Open Angle Glaucoma (POAG)1 Primary Open-Angle Glaucoma (POAG)1

Leading sponsors

University of Nebraska2 Adapt Produtos Oftalmológicos Ltda.1 Afyon Kocatepe University Hospital1 Alcon Research1 Alleanza Pharmaceuticals, Inc.1 Aristotle University Of Thessaloniki1 Aurolab1 Bausch & Lomb Incorporated1 Chong Kun Dang Pharmaceutical1 Daniel Moore1 Hoffmann-La Roche1 Inotek Pharmaceuticals Corporation1 Intuor Technologies, Inc.1 Kubota Vision Inc.1 Massachusetts Eye and Ear Infirmary1

Trial status mix

COMPLETED19

UNKNOWN6

TERMINATED4

ACTIVE_NOT_RECRUITING1

WITHDRAWN1

Phase mix

PHASE210

PHASE37

PHASE47

PHASE15

NA4

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.